A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer von Drilon, Alexander, Somwar, Romel, Wagner, Jacob P, Vellore, Nadeem A, Eide, Christopher A, Zabriskie, Matthew S, Arcila, Maria E, Hechtman, Jaclyn F, Wang, Lu, Smith, Roger S, Kris, Mark G, Riely, Gregory J, Druker, Brian J, O'Hare, Thomas, Ladanyi, Marc, Davare, Monika A

Volltext

Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain von Jones, Kristen, Keddy, Clare, Jenkins, Chelsea, Nicholson, Katelyn, Shinde, Ujwal, Davare, Monika A.

Volltext

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors von Davare, Monika A., Vellore, Nadeem A., Wagner, Jacob P., Eide, Christopher A., Goodman, James R., Drilon, Alexander, Deininger, Michael W., O’Hare, Thomas, Druker, Brian J.

Volltext

Subtle sequence variations alter tripartite complex kinetics and G-quadruplex dynamics in RNA aptamer Broccoli von Savage, Jonathan C, Davare, Monika A, Shinde, Ujwal

Volltext

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes von Hosseini, Mona M., Kurtz, Stephen E., Abdelhamed, Sherif, Mahmood, Shawn, Davare, Monika A., Kaempf, Andy, Elferich, Johannes, McDermott, Jason E., Liu, Tao, Payne, Samuel H., Shinde, Ujwal, Rodland, Karin D., Mori, Motomi, Druker, Brian J., Singer, Jack W., Agarwal, Anupriya

Volltext

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins von Davare, Monika A., Saborowski, Anna, Eide, Christopher A., Tognon, Cristina, Smith, Rebecca L., Elferich, Johannes, Agarwal, Anupriya, Tyner, Jeffrey W., Shinde, Ujwal P., Lowe, Scott W., Druker, Brian J.

Volltext

Long-term potentiation-dependent spine enlargement requires synaptic Ca2+-permeable AMPA receptors recruited by CaM-kinase I von Fortin, Dale A, Davare, Monika A, Srivastava, Taasin, Brady, James D, Nygaard, Sean, Derkach, Victor A, Soderling, Thomas R

Volltext

Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma von Davis, Lara E, Nusser, Kevin D, Przybyl, Joanna, Pittsenbarger, Janét, Hofmann, Nicolle E, Varma, Sushama, Vennam, Sujay, Debiec-Rychter, Maria, van de Rijn, Matt, Davare, Monika A

Volltext

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors von Iyer, Sudarshan R, Nusser, Kevin, Jones, Kristen, Shinde, Pushkar, Keddy, Clare, Beach, Catherine Z, Aguero, Erin, Force, Jeremy, Shinde, Ujwal, Davare, Monika A

Volltext

Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target von Saborowski, Anna, Saborowski, Michael, Davare, Monika A., Druker, Brian J., Klimstra, David S., Lowe, Scott W.

Volltext

ROS1-dependent cancers — biology, diagnostics and therapeutics von Drilon, Alexander, Jenkins, Chelsea, Iyer, Sudarshan, Schoenfeld, Adam, Keddy, Clare, Davare, Monika A.

Volltext

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors von Somwar, Romel, Hofmann, Nicolle E., Smith, Bryan, Odintsov, Igor, Vojnic, Morana, Linkov, Irina, Tam, Ashley, Khodos, Inna, Mattar, Marissa S., de Stanchina, Elisa, Flynn, Daniel, Ladanyi, Marc, Drilon, Alexander, Shinde, Ujwal, Davare, Monika A.

Volltext

RET inhibition in novel patient-derived models of RET fusion-positive lung adenocarcinoma reveals a role for MYC upregulation von Hayashi, Takuo, Odintsov, Igor, Smith, Roger S., Ishizawa, Kota, Liu, Allan J. W., Delasos, Lukas, Kurzatkowski, Christopher, Tai, Huichun, Gladstone, Eric, Vojnic, Morana, Kohsaka, Shinji, Suzawa, Ken, Liu, Zebing, Kunte, Siddharth, Mattar, Marissa S., Khodos, Inna, Davare, Monika A., Drilon, Alexander, Cheng, Emily, de Stanchina, Elisa, Ladanyi, Marc, Somwar, Romel

Volltext

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers von Thawani, Rajat, Repetto, Matteo, Keddy, Clare, Nicholson, Katelyn, Jones, Kristen, Nusser, Kevin, Beach, Catherine Z., Harada, Guilherme, Drilon, Alexander, Davare, Monika A.

Volltext

Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers von Thawani, Rajat, Repetto, Matteo, Keddy, Clare, Nicholson, Katelyn, Jones, Kristen, Nusser, Kevin, Beach, Catherine Z., Harada, Guilherme, Drilon, Alexander, Davare, Monika A.

Volltext

Discovery and Validation of a Compound to Target Ewing's Sarcoma von Esfandiari Nazzaro, Ellie, Sabei, Fahad Y., Vogel, Walter K., Nazari, Mohamad, Nicholson, Katelyn S., Gafken, Philip R., Taratula, Olena, Taratula, Oleh, Davare, Monika A., Leid, Mark

Volltext

Critical Role of cAMP-Dependent Protein Kinase Anchoring to the L-Type Calcium Channel Cav1.2 via A-Kinase Anchor Protein 150 in Neurons von Hall, Duane D, Davare, Monika A, Shi, Mei, Allen, Margaret L, Weisenhaus, Michael, McKnight, G. Stanley, Hell, Johannes W

Volltext

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer von Schoenfeld, Adam J, Chan, Joseph M, Kubota, Daisuke, Sato, Hiroki, Rizvi, Hira, Daneshbod, Yahya, Chang, Jason C, Paik, Paul K, Offin, Michael, Arcila, Maria E, Davare, Monika A, Shinde, Ujwal, Pe'er, Dana, Rekhtman, Natasha, Kris, Mark G, Somwar, Romel, Riely, Gregory J, Ladanyi, Marc, Yu, Helena A

Volltext

Functional impact and targetability of PI3KCA , GNAS , and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation von Choo, Florence, Odintsov, Igor, Nusser, Kevin, Nicholson, Katelyn S, Davis, Lara, Corless, Christopher L, Stork, Linda, Somwar, Romel, Ladanyi, Marc, Davis, Jessica L, Davare, Monika A

Volltext

Therapeutically Targetable ALK Mutations in Leukemia von Maxson, Julia E, Davare, Monika A, Luty, Samuel B, Eide, Christopher A, Chang, Bill H, Loriaux, Marc M, Tognon, Cristina E, Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K, Druker, Brian J, Tyner, Jeffrey W

Volltext